$HBIO
HARVARD BIOSCIENCE INC Stock $hbio

$hbio Overview Financials Valuation SEC Filings Company Website

2016 Q2 Form 10-Q Financial Statement

#000117184316011528 Filed on August 04, 2016

Income Statement

Concept	2016 Q2	2015 Q2
Revenue	$26.14M	$28.80M
YoY Change	-9.25%	6.83%
Cost Of Revenue	$14.46M	$16.21M
YoY Change	-10.76%	10.39%
Gross Profit	$11.68M	$12.60M
YoY Change	-7.3%	2.58%
Gross Profit Margin	44.67%	43.73%
Selling, General & Admin	$10.32M	$10.05M
YoY Change	2.69%	17.49%
% of Gross Profit	88.39%	79.79%
Research & Development	$1.502M	$1.714M
YoY Change	-12.37%	33.49%
% of Gross Profit	12.87%	13.61%
Depreciation & Amortization	$1.120M	$1.090M
YoY Change	2.75%	19.78%
% of Gross Profit	9.59%	8.65%
Operating Expenses	$12.52M	$12.50M
YoY Change	0.15%	18.56%
Operating Profit	-$840.0K	$99.00K
YoY Change	-948.48%	-94.3%
Interest Expense	$180.0K	$215.0K
YoY Change	-16.28%	-13.31%
% of Operating Profit		217.17%
Other Income/Expense, Net	$73.00K	-$526.0K
YoY Change	-113.88%	12.39%
Pretax Income	-$767.0K	-$427.0K
YoY Change	79.63%	-133.62%
Income Tax	-$54.00K	-$776.0K
% Of Pretax Income
Net Earnings	-$713.0K	$349.0K
YoY Change	-304.3%	-65.85%
Net Earnings / Revenue	-2.73%	1.21%
Basic Earnings Per Share	-$0.02	$0.01
Diluted Earnings Per Share	-$0.02	$0.01
COMMON SHARES
Basic Shares Outstanding	34.13M shares	33.57M shares
Diluted Shares Outstanding	34.13M shares	35.03M shares

Balance Sheet

Concept	2016 Q2	2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.600M	$7.400M
YoY Change	-51.35%	-71.97%
Cash & Equivalents	$3.631M	$6.090M
Short-Term Investments
Other Short-Term Assets	$0.00	$4.922M
YoY Change	-100.0%	159.05%
Inventory	$22.20M	$23.07M
Prepaid Expenses
Receivables	$16.30M	$18.54M
Other Receivables	$4.700M	$5.000M
Total Short-Term Assets	$46.80M	$56.54M
YoY Change	-17.23%	-12.2%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.600M	$5.764M
YoY Change	-2.85%	40.59%
Goodwill		$41.08M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.000M	$406.0K
YoY Change	146.31%	-96.97%
Total Long-Term Assets	$67.30M	$82.04M
YoY Change	-17.96%	11.92%
TOTAL ASSETS
Total Short-Term Assets	$46.80M	$56.54M
Total Long-Term Assets	$67.30M	$82.04M
Total Assets	$114.1M	$138.6M
YoY Change	-17.66%	0.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.600M	$8.834M
YoY Change	-25.29%	73.22%
Accrued Expenses	$4.000M	$4.438M
YoY Change	-9.87%	-3.52%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.400M	$5.000M
YoY Change	-52.0%	0.0%
Total Short-Term Liabilities	$14.90M	$21.23M
YoY Change	-29.83%	29.47%
LONG-TERM LIABILITIES
Long-Term Debt	$13.80M	$15.65M
YoY Change	-11.82%	-9.54%
Other Long-Term Liabilities	$2.700M	$4.700M
YoY Change	-42.55%	-17.54%
Total Long-Term Liabilities	$16.50M	$15.65M
YoY Change	5.43%	-31.96%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.90M	$21.23M
Total Long-Term Liabilities	$16.50M	$15.65M
Total Liabilities	$37.40M	$43.76M
YoY Change	-14.54%	10.79%
SHAREHOLDERS EQUITY
Retained Earnings		-$93.74M
YoY Change
Common Stock		$210.2M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares		7.746M shares
Shareholders Equity	$76.70M	$94.81M
YoY Change
Total Liabilities & Shareholders Equity	$114.1M	$138.6M
YoY Change	-17.66%	0.64%

Cashflow Statement

Concept	2016 Q2	2015 Q2
OPERATING ACTIVITIES
Net Income	-$713.0K	$349.0K
YoY Change	-304.3%	-65.85%
Depreciation, Depletion And Amortization	$1.120M	$1.090M
YoY Change	2.75%	19.78%
Cash From Operating Activities	$950.0K	-$480.0K
YoY Change	-297.92%	-133.8%
INVESTING ACTIVITIES
Capital Expenditures	-$200.0K	-$600.0K
YoY Change	-66.67%	30.43%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$20.00K
YoY Change	-100.0%	-166.67%
Cash From Investing Activities	-$200.0K	-$580.0K
YoY Change	-65.52%	16.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-900.0K	200.0K
YoY Change	-550.0%	-135.09%
NET CHANGE
Cash From Operating Activities	950.0K	-480.0K
Cash From Investing Activities	-200.0K	-580.0K
Cash From Financing Activities	-900.0K	200.0K
Net Change In Cash	-150.0K	-860.0K
YoY Change	-82.56%	-345.71%
FREE CASH FLOW
Cash From Operating Activities	$950.0K	-$480.0K
Capital Expenditures	-$200.0K	-$600.0K
Free Cash Flow	$1.150M	$120.0K
YoY Change	858.33%	-93.62%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2016Q2	us-gaap	Interest Expense InterestExpense	180000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2136000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	95000	USD
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	HARVARD BIOSCIENCE INC
	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2015Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5128000	USD
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5236000	USD
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4922000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1502000	USD
CY2015Q2	us-gaap	Restructuring Charges RestructuringCharges	54000	USD
CY2015Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	678000	USD
CY2016Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	282000	USD
CY2016Q2	us-gaap	Other Interest And Dividend Income OtherInterestAndDividendIncome	0	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	1653000	USD
	us-gaap	Depreciation Depreciation	769000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-11000	USD
	hbio	Non Cash Restructuring Charge NonCashRestructuringCharge	0	USD
	hbio	Non Cash Restructuring Charge NonCashRestructuringCharge	-64000	USD
	hbio	Amortization Of Catalog Costs AmortizationOfCatalogCosts	6000	USD
	hbio	Amortization Of Catalog Costs AmortizationOfCatalogCosts	8000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	44000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	56000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	30000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	4000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2634000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1027000	USD
CY2015Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-134000	USD
CY2015Q2	us-gaap	Interest Expense InterestExpense	215000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	1272000	USD
	us-gaap	Depreciation Depreciation	809000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-959000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1242000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	865000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	240000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-2459000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	2451000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-114000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-395000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	13000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-660000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	188000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	216000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-4000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-396000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	216000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-981000	USD
	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	402000	USD
	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	1640000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	15000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	4545000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-412000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6170000	USD
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	2000000	USD
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	4050000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	4625000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	4850000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	-9000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1864000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1032000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0145	pure
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-283000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-6732000	USD
	us-gaap	Interest Paid InterestPaid	312000	USD
	us-gaap	Interest Paid InterestPaid	427000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	452000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	312000	USD
CY2016Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	10093000	USD
CY2016Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	1084000	USD
CY2016Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	11032000	USD
CY2016Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	22068000	USD
CY2016Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	16427000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8782000	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1711000	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1707000	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1600000	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	1422000	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	1210000	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	3552000	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	11202000	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2700000	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2500000	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2300000	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2200000	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	2200000	USD
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1821000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1760000	USD
CY2016Q2	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-12000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-12000	USD
CY2016Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-10000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-24000	USD
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2536000	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2121000	USD
CY2016Q2	hbio	Total Indefinite Lived Intangible Assets Including Goodwill TotalIndefiniteLivedIntangibleAssetsIncludingGoodwill	40960000	USD
CY2016Q2	hbio	Total Intangible Assets TotalIntangibleAssets	88335000	USD
CY2016Q2	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	168000	USD
CY2016Q2	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	181000	USD
CY2016Q2	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-79000	USD
CY2016Q2	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	66000	USD
CY2016Q2	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	193000	USD
CY2015Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	147000	USD
CY2015	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	-81000	USD
CY2015	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	-24000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6744000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7402000	USD
	dei	Entity Central Index Key EntityCentralIndexKey	0001123494
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-23000	USD
CY2016Q2	us-gaap	Secured Debt SecuredDebt	16163000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	21920000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	16018000	USD
CY2015Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	10957000	USD
CY2015Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	888000	USD
CY2015Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	10498000	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	47375000	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-27758000	USD
CY2015Q4	hbio	Total Indefinite Lived Intangible Assets Including Goodwill TotalIndefiniteLivedIntangibleAssetsIncludingGoodwill	41580000	USD
CY2015Q4	hbio	Total Intangible Assets TotalIntangibleAssets	89159000	USD
CY2014Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	252000	USD
CY2016Q2	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	0	USD
CY2015Q2	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	0	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	941190	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.4139	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.4108	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0172	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y3M7D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M7D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation ShareBasedCompensation	1653000	USD
CY2016Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34127131	shares
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33569180	shares
CY2016Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2015Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1456470	shares
CY2016Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34127131	shares
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35025650	shares
CY2015Q2	hbio	Increase In Number Of Shares Authorized For Issuance Under Stock Option And Incentive Plan IncreaseInNumberOfSharesAuthorizedForIssuanceUnderStockOptionAndIncentivePlan	2500000	shares
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	32000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	47579000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-26707000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17547000	USD
CY2015Q4	us-gaap	Assets Assets	120050000	USD
CY2015Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1223000	USD
CY2015Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3873000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	22343000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	995000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	20872000	USD
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	310000	USD
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41724772	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33979265	shares
CY2015Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	7745507	shares
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	42000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	50549000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	152000	USD
CY2015Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	2364000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	752000	USD
CY2015Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	290000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4021000	USD
CY2015Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	868000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19323000	USD
CY2015Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	16369000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	3775000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	2985000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	42452000	USD
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	416000	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	211457000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-111723000	USD
CY2015Q4	us-gaap	Treasury Stock Carrying Basis TreasuryStockCarryingBasis	10668000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	120050000	USD
CY2015Q4	us-gaap	Goodwill Goodwill	40357000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Current DeferredTaxLiabilitiesCurrent	2246000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5902000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	77598000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	313559	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	5.29
CY2015Q2	us-gaap	Revenues Revenues	28800000	USD
CY2015Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	16205000	USD
CY2015Q2	us-gaap	Gross Profit GrossProfit	12595000	USD
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	12496000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	99000	USD
CY2015Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-526000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-427000	USD
CY2015Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-776000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	349000	USD
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
	us-gaap	Goodwill Translation Adjustments GoodwillTranslationAdjustments	-672000	USD
	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div><p style='text-align:left;margin-top:9pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0pt;' >2</font><font style='font-family:Times New Roman;font-size:10pt;font-weight:bold;' >.</font><font style='font-family:Times New Roman;font-size:10pt;font-weight:bold;' > Recently Issued Accounting Pronouncements</font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Calibri;font-size:11pt;font-weight:bold;margin-left:0pt;' > </font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;' >In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >“Revenue from Contracts with Customers,”</font><font style='font-family:Times New Roman;font-size:10pt;' > a new accounting standard that provides for a comprehensive model to use in the accounting for revenue arising from contracts with customers that will replace most existing revenue recognition guidance within generally accepted accounting principles in th</font><font style='font-family:Times New Roman;font-size:10pt;' >e United States. Under this standard, revenue will be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or servi</font><font style='font-family:Times New Roman;font-size:10pt;' >ces. At its July 2015 meeting, the FASB agreed to defer the mandatory effective date of ASU 2014-09 one year. Under the one year deferral, the standard will take effect in 2018 for calendar year-end public entities. The Company is assessing the new standar</font><font style='font-family:Times New Roman;font-size:10pt;' >d and has not yet determined the impact to the consolidated financial statements.</font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;' > </font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;' >In July 2015, the FASB issued ASU 2015-11, </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >Simplifying Measurement of Inventory</font><font style='font-family:Times New Roman;font-size:10pt;' >. The update requires measurement of most inventory “at the lower of cost and net realizable </font><font style='font-family:Times New Roman;font-size:10pt;' >value”, and applies to all entities that recognize inventory within the scope of ASC 330, except for inventory measured under the last-in, first-out (LIFO) method or the retail inventory method (RIM). ASU 2015-11 requires prospective application and repres</font><font style='font-family:Times New Roman;font-size:10pt;' >ents a change in accounting principle. The update is effective for fiscal years beginning after December 15, 2016.  Early adoption is permitted for financial statements that have not been previously issued. The Company is evaluating the impact of ASU 2015-</font><font style='font-family:Times New Roman;font-size:10pt;' >11 on its consolidated financial statements and the possibility of early adoption by the Company.</font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;' > </font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;' >In February 2016, the FASB issued ASU 2016-02, </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >Leases</font><font style='font-family:Times New Roman;font-size:10pt;' >, which is intended to improve financial reporting about leasing transactions. The update requires a lessee to record on the balance shee</font><font style='font-family:Times New Roman;font-size:10pt;' >t the assets and liabilities for the rights and obligations created by lease terms of more than 12 months. The update is effective for fiscal years beginning after December 15, 2018. The Company is evaluating the impact of ASU 2016-02 on its consolidated f</font><font style='font-family:Times New Roman;font-size:10pt;' >inancial statements.</font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;color:#000000;' >In March 2016, the FASB issued ASU 2016-09, </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;color:#000000;' >Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >, which simplifies the accounting for share-based payment transactions, including the in</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >come tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. </font><font style='font-family:Times New Roman;font-size:10pt;' >The update is effective for fiscal years be</font><font style='font-family:Times New Roman;font-size:10pt;' >ginning after December 15, 2016 </font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >and early adoption is permitted. </font><font style='font-family:Times New Roman;font-size:10pt;' >The Company is ev</font><font style='font-family:Times New Roman;font-size:10pt;' >aluating the impact of ASU 2016-09 on its consolidated financial statements.</font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;' >In June 2016, the FASB issued ASU 2016-13, </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >Financial Instruments – Credit Losses (Topic 326), Measurement of credit losses on Financial Instruments. </font><font style='font-family:Times New Roman;font-size:10pt;' >The update</font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' > </font><font style='font-family:Times New Roman;font-size:10pt;' >amends the FASB</font><font style='font-family:Times New Roman;font-size:10pt;' >’s </font><font style='font-family:Times New Roman;font-size:10pt;' >guidance on the impairment of financial instruments. The ASU adds to U.S. GAAP an impairment model (known as the current expected credit loss (CECL) model) that is based on expected losses rather than incurred losses. Under the new guidance, an entity reco</font><font style='font-family:Times New Roman;font-size:10pt;' >gnizes as an allowance its estimate of expected credit losses, which the FASB believes will result in more ti</font><font style='font-family:Times New Roman;font-size:10pt;' >mely recognition of such losses. </font><font style='font-family:Times New Roman;font-size:10pt;' >The</font><font style='font-family:Times New Roman;font-size:10pt;' > ASU is effective for fiscal years beginning after December 15, 2019, </font><font style='font-family:Times New Roman;font-size:10pt;' >including interim periods within those fiscal years. T</font><font style='font-family:Times New Roman;font-size:10pt;' >he Company is evaluating the impact of ASU 2016-13 on its consolidated financial statements.</font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:24.5pt;' >Recently Adopted Acc</font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >ounting Pronouncements</font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:inherit;font-size:10pt;margin-left:24.5pt;' >In April 2015, the FASB issued ASU 2015-03, </font><font style='font-family:inherit;font-size:10pt;font-style:italic;' >Interest - Imputation of Interest - Simplifying the Presentation of Debt Issuance Costs</font><font style='font-family:inherit;font-size:10pt;' >. Under this guidance, debt issuance costs related to a recognized debt liability should be presented</font><font style='font-family:inherit;font-size:10pt;' > in the balance sheet as a direct deduction from the carrying amount of that debt liability. The provisions of this guidance are to be applied retrospectively and are effective for interim and annual periods beginning after December 15, 2015. The Company a</font><font style='font-family:inherit;font-size:10pt;' >dopted this guidance during the </font><font style='font-family:inherit;font-size:10pt;' >six months ended</font><font style='font-family:inherit;font-size:10pt;' > </font><font style='font-family:inherit;font-size:10pt;' >June 30,</font><font style='font-family:inherit;font-size:10pt;' > </font><font style='font-family:inherit;font-size:10pt;' >2016</font><font style='font-family:inherit;font-size:10pt;' >. The consolidated balance sheet as of December 31, </font><font style='font-family:inherit;font-size:10pt;' >2015</font><font style='font-family:inherit;font-size:10pt;' >, included in these consolidated financial statements, reflects a restatement to reclassify unamortized deferred fina</font><font style='font-family:inherit;font-size:10pt;' >ncing costs of approximately $0.2 million from other long-term assets to long-term debt. For deferred financing costs paid to secure long-term debt, the Company made a policy election to present such costs as a direct deduction from the debt liability on t</font><font style='font-family:inherit;font-size:10pt;' >he consolidated balance sheet.</font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;' >In September 2015, the FASB issued ASU 2015-16, </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >Simplifying</font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' > the Accounting for Measurement-Period Adjustments</font><font style='font-family:Times New Roman;font-size:10pt;' >. The update eliminates the requirement to retrospectively adjust financial statements for measurement-period adjustments that occur in periods after a business combination. Under the update, measurement-period adjustments are to be calculated as if they were known at the acquisition date, but are recognized in the reporting period in which they are determined. Additional disclosures are required about the impact on current-period earnings. ASU 2015-16 requires prospective application to adjustments of provisional amounts that occur after the effective </font><font style='font-family:Times New Roman;font-size:10pt;' >date. The update wa</font><font style='font-family:Times New Roman;font-size:10pt;' >s effective for fiscal years beginning after December 15, 201</font><font style='font-family:Times New Roman;font-size:10pt;' >5</font><font style='font-family:Times New Roman;font-size:10pt;' >.  </font><font style='font-family:Times New Roman;font-size:10pt;' >The Company adopted ASU 2015-16 on January 1, 2016. The adoption of ASU 2015-16 did not have a material impact</font><font style='font-family:Times New Roman;font-size:10pt;' > on its consolidated financial statements.</font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;' >In November 2015, the FASB issued ASU 2015-17, </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >Balance Sheet Classification of Deferred Taxes</font><font style='font-family:Times New Roman;font-size:10pt;' >. The update requires all deferred income taxes to be presented on the balance sheet as noncurrent. The new guidance is intended to</font><font style='font-family:Times New Roman;font-size:10pt;' > simplify financial reporting by eliminating the requirement to classify deferred taxes between current and noncurrent. The update is effective for fiscal years beginning after December 15, 2016.  Early adoption is permitted at the beginning of an interim </font><font style='font-family:Times New Roman;font-size:10pt;' >or annual period. </font><font style='font-family:Times New Roman;font-size:10pt;' >During the </font><font style='font-family:Times New Roman;font-size:10pt;' >six months ended</font><font style='font-family:Times New Roman;font-size:10pt;' > </font><font style='font-family:Times New Roman;font-size:10pt;' >June 30,</font><font style='font-family:Times New Roman;font-size:10pt;' > </font><font style='font-family:Times New Roman;font-size:10pt;' >2016</font><font style='font-family:Times New Roman;font-size:10pt;' >, t</font><font style='font-family:Times New Roman;font-size:10pt;' >he Company </font><font style='font-family:Times New Roman;font-size:10pt;' >early adopted the new guidance on a prospective basis and has presented all deferred tax assets and deferred tax liabilities as noncurrent in the consolidated balance sheet</font><font style='font-family:Times New Roman;font-size:10pt;' > at </font><font style='font-family:Times New Roman;font-size:10pt;' >June 30,</font><font style='font-family:Times New Roman;font-size:10pt;' > </font><font style='font-family:Times New Roman;font-size:10pt;' >2016</font><font style='font-family:Times New Roman;font-size:10pt;' >.</font></p></div>
	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	-41000	USD
	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	87000	USD
CY2015Q2	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-81000	USD
CY2015Q2	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	92000	USD
CY2016Q2	us-gaap	Defined Benefit Plans Estimated Future Employer Contributions In Current Fiscal Year DefinedBenefitPlansEstimatedFutureEmployerContributionsInCurrentFiscalYear	600000	USD
CY2016Q2	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	200000	USD
CY2015Q2	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	200000	USD
CY2016Q2	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	2600000	USD
CY2015Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	2800000	USD
CY2016Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	500000	USD
CY2015Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	400000	USD
CY2016Q2	hbio	Minimun Percentage Of Term Loan And Delayed Draw Term Loan On Which Interest Rate Required To Be Fixed MinimunPercentageOfTermLoanAndDelayedDrawTermLoanOnWhichInterestRateRequiredToBeFixed	0.5	pure
CY2016Q2	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	-112000	USD
CY2015Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	-167000	USD
CY2016Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5502327	shares
CY2015Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1264875	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	17508929	shares
CY2016Q2	hbio	Weighted Average Estimated Black Scholes Value Of Option Grants WeightedAverageEstimatedBlackScholesValueOfOptionGrants	1.48
CY2015Q2	hbio	Weighted Average Estimated Black Scholes Value Of Option Grants WeightedAverageEstimatedBlackScholesValueOfOptionGrants	2.08
	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	362000	USD
	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	336000	USD
	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-159000	USD
	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	133000	USD
	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	367000	USD
	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	345000	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-796000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1140000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2191000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1139000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1052000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-2737000	USD
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-71000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	28479000	USD
	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-156000	USD
	us-gaap	Defined Benefit Plan Recognized Net Gain Loss Due To Curtailments DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments	0	USD
	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	178000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3462000	USD
	us-gaap	Restructuring Charges RestructuringCharges	111000	USD
	us-gaap	Operating Expenses OperatingExpenses	25124000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1051000	USD
	us-gaap	Interest Expense InterestExpense	437000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	89000	USD
	us-gaap	Other Interest And Dividend Income OtherInterestAndDividendIncome	4000	USD
	us-gaap	Gross Profit GrossProfit	24620000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	10188000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11184000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2927000	USD
	us-gaap	Restructuring Charges RestructuringCharges	12000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1370000	USD
	us-gaap	Operating Expenses OperatingExpenses	25681000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1061000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	273000	USD
	us-gaap	Interest Expense InterestExpense	344000	USD
	us-gaap	Other Interest And Dividend Income OtherInterestAndDividendIncome	1000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-79000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-149000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1210000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	139000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1349000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1205000	USD
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-48000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	23000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	50000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3810000	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
	us-gaap	Revenues Revenues	53099000	USD
	us-gaap	Revenues Revenues	54563000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	30490000	USD
	us-gaap	Gross Profit GrossProfit	24073000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	10327000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9753000	USD
	dei	Document Period End Date DocumentPeriodEndDate	2016-06-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2016Q2	hbio	Business Acquisition Direct Acquisition Costs In Income Statement BusinessAcquisitionDirectAcquisitionCostsInIncomeStatement	0	USD
	hbio	Business Acquisition Direct Acquisition Costs In Income Statement BusinessAcquisitionDirectAcquisitionCostsInIncomeStatement	6000	USD
CY2015Q2	hbio	Business Acquisition Direct Acquisition Costs In Income Statement BusinessAcquisitionDirectAcquisitionCostsInIncomeStatement	200000	USD
	hbio	Business Acquisition Direct Acquisition Costs In Income Statement BusinessAcquisitionDirectAcquisitionCostsInIncomeStatement	800000	USD
	us-gaap	Goodwill Other Changes GoodwillOtherChanges	50000	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2016Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-13114000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2579000	USD
	hbio	Estimated Rental Expenses Current Year EstimatedRentalExpensesCurrentYear	1900000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	800000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1000000	USD
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.531	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.115	pure
	hbio	Minimun Percentage Of Term Loan And Delayed Draw Term Loan On Which Interest Rate Required To Be Fixed MinimunPercentageOfTermLoanAndDelayedDrawTermLoanOnWhichInterestRateRequiredToBeFixed	0.5	pure
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-11884000	USD
	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-1253000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1230000	USD
	us-gaap	Defined Benefit Plans Estimated Future Employer Contributions In Current Fiscal Year DefinedBenefitPlansEstimatedFutureEmployerContributionsInCurrentFiscalYear	600000	USD
	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	400000	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.4291	pure
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.014	pure
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.3935	pure
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.017	pure
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2016Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y1M28D
CY2015Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y3M10D
CY2016Q2	us-gaap	Share Based Compensation ShareBasedCompensation	899000	USD
CY2015Q2	us-gaap	Share Based Compensation ShareBasedCompensation	692000	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	-338532	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34070241	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33240467	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34070241	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33240467	shares
CY2016Q2	hbio	Percentage Of Outstanding Common Stock PercentageOfOutstandingCommonStock	0.2	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate	0.85	pure
CY2016Q2	hbio	Employee Stock Purchase Plan Shares Authorized EmployeeStockPurchasePlanSharesAuthorized	750000	shares
CY2016Q2	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	39353	shares
CY2015Q2	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	26181	shares
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	683364	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5502327	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5169376	shares
	hbio	Weighted Average Estimated Black Scholes Value Of Option Grants WeightedAverageEstimatedBlackScholesValueOfOptionGrants	1.26
	hbio	Weighted Average Estimated Black Scholes Value Of Option Grants WeightedAverageEstimatedBlackScholesValueOfOptionGrants	2.21

Files In Submission

Name	View Source	Status
0001171843-16-011528-index-headers.html	Edgar Link	pending
0001171843-16-011528-index.html	Edgar Link	pending
0001171843-16-011528.txt	Edgar Link	pending
0001171843-16-011528-xbrl.zip	Edgar Link	pending
exh_101.htm	Edgar Link	pending
exh_311.htm	Edgar Link	pending
exh_312.htm	Edgar Link	pending
exh_321.htm	Edgar Link	pending
exh_322.htm	Edgar Link	pending
f10q_080416.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
hbio-20160630.xml	Edgar Link	completed
hbio-20160630.xsd	Edgar Link	pending
hbio-20160630_cal.xml	Edgar Link	unprocessable
hbio-20160630_def.xml	Edgar Link	unprocessable
hbio-20160630_lab.xml	Edgar Link	unprocessable
hbio-20160630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HBIO
HARVARD BIOSCIENCE INC Stock $hbio

2016 Q2 Form 10-Q Financial Statement

#000117184316011528 Filed on August 04, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HBIO HARVARD BIOSCIENCE INC Stock $hbio

2016 Q2 Form 10-Q Financial Statement

#000117184316011528 Filed on August 04, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HBIO
HARVARD BIOSCIENCE INC Stock $hbio